New gel could zap away common warts in just weeks

NCT ID NCT07246590

Recruiting now Disease control Sponsor: Verrica Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a gel called YCANTH on common warts caused by HPV. About 300 people aged 2 and older with at least one wart will apply the gel or a fake version. The goal is to see if the gel can clear all warts by day 84.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COMMON WARTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

common wart human papilloma virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COMMON WARTS COMMON WARTS (VERRUCA VULGARIS) HUMAN PAPILLOMA VIRUS (HPV) WARTS

Contacts and locations

Locations

Anne Arundel Dermatology, PA dba Maryland Dermatology Laser Skin & Vein
RECRUITING

Hunt Valley, Maryland, 31030, United States
Florida Center for Dermatology, P.A.
RECRUITING

Saint Augustine, Florida, 32080, United States
Tennessee Clinical Research Center, Inc.
RECRUITING

Nashville, Tennessee, 37215, United States
Texas Dermatology and Laser Specialists
RECRUITING

San Antonio, Texas, 78218, United States
The Indiana Clinical Trials Center, PC
RECRUITING

Plainfield, Indiana, 46168, United States
The University of Texas Health Science Center at Houston
NOT_YET_RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.